Monsanto’s smear merchant, the Genetic Literacy Project, is now Bayer’s bully
By Jonathan Matthews,
GMWatch
| 08. 31. 2022
Recently the Genetic Literacy Project has been heavily targeting critics of the herbicide Roundup, now owned by Bayer, with a barrage of articles, podcasts, and tweets, in which the controversial University of Florida scientist Kevin Folta has been much to the fore.
It all started when the Guardian published a piece by the award-winning journalist Carey Gillam on a CDC study showing the prevalence in urine samples in the US of Roundup’s controversial active ingredient glyphosate, which has been linked to cancer.
Kevin Folta led the charge for the GLP with a piece that labelled the Guardian article the latest example of “yellow journalism” (i.e. lurid, sensationalist reporting), not to mention “deceptive journalism”, by “scientifically illiterate journalists”. Folta then gave over a further three paragraphs to attacking Gillam personally and outlining his version of her “ethically questionable history”. This somehow failed to mention that, among other things, she won a Society of Environmental Journalists’ book award or that her former colleagues at Reuters say she is “an exceptional journalist” who produces “impeccably reported” stories.
“Slimeball tactics”
The GLP, which has...
Related Articles
By Liyan Qi and Jonathan Cheng, The Wall Street Journal | 03.26.2025
photo via Wikimedia Commons licensed under CC by 3.0
Chinese scientist He Jiankui set off global outrage and landed in prison after he skirted ethical guidelines and claimed he had produced genetically modified babies designed to resist HIV infection.
Now, the self-styled ...
By Carsten T. Charlesworth, Henry T. Greely, and Hiromitsu Nakauchi, MIT Technology Review | 03.25.2025
Why do we hear about medical breakthroughs in mice, but rarely see them translate into cures for human disease? Why do so few drugs that enter clinical trials receive regulatory approval? And why is the waiting list for organ transplantation...
By Anna Louie Sussman, The New York Times | 03.25.2025
On June 24, 2022, the same day the Supreme Court issued its decision in Dobbs v. Jackson Women’s Health Organization, I received a call from the fertility clinic where I’d been undergoing in vitro fertilization, informing me that seven of...
By Michael Gibney, PharmaVoice | 03.20.2025
The death this week of a teenager receiving Sarepta Therapeutics’ gene therapy Elevidys for Duchenne muscular dystrophy is a tragic reminder of the stakes involved in cutting-edge biotech innovation.
While gene therapies like Sarepta’s offer an opportunity to treat and...